R. Mass

New School — United States

Medicine · Health Sciences

22h-index4.4kcitations53works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(14), Colorectal Cancer Treatments and Studies(13), Cancer Treatment and Pharmacology(13), Monoclonal and Polyclonal Antibodies Research(8), Lung Cancer Research Studies(8)

Publications52 total

Joseph Heath’s Ethics for Capitalists: The Market Failures Approach 2.0
Journal of Business Ethics·2024· 2 cited
Hydrochar enhances growth of poplar for bioenergy while marginally contributing to direct soil carbon sequestration
GCB Bioenergy·2017· 45 citedOpen Access
A banker’s code of ethics
Oxford Review of Economic Policy·2017· 6 cited
ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study.
Journal of Clinical Oncology·2012· 1 cited
General & clinical epidemiology CKD 1-5 (1)
Clinical Kidney Journal·2011Open Access
Progression & risk factors CKD 1-5 (1)
Clinical Kidney Journal·2011Open Access
CCK-4 effects upon facial expression in healthy subjects
Pharmacopsychiatry·2009
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
Journal of Clinical Oncology·2008· 171 citedOpen Access
The Development of Avastin
2007· 1 cited
Osteosarcoma in children aged less than five years at diagnosis: Experience of the Cooperative Osteosarcoma Study Group
Journal of Clinical Oncology·2007· 1 cited
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Annual Review of Medicine·2006· 235 cited
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107
Journal of Clinical Oncology·2006· 4 cited
In Reply:
Journal of Clinical Oncology·2006· 2 citedOpen Access
erb-B2 as a Therapeutic Target
Humana Press eBooks·2006· 1 cited
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
Breast Cancer Research and Treatment·2005· 212 cited
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab
Clinical Breast Cancer·2005· 364 cited
A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization
Journal of Clinical Oncology·2005· 17 cited
Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies
Journal of Clinical Oncology·2005· 58 cited
Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC)
Journal of Clinical Oncology·2005· 22 cited
Association of topoisomerase II-alpha (TOP2A) gene amplification with responsiveness to anthracycline-containing chemotherapy among women with metastatic breast cancer entered in the Herceptin H0648g pivotal clinical trial
Journal of Clinical Oncology·2005· 10 cited
page 1 of 3Next →

Frequent Co-authors

Fairooz F. Kabbinavar(7), William Novotny(7), Somnath Sarkar(7), Herbert I. Hurwitz(6), Roy S. Herbst(5), DJ Slamon(5), Melody Cobleigh(4), Eric D. Mininberg(3), T. Henderson(3), Ramesh K. Ramanathan(3), Alan B. Sandler(3), G. Fyfe(3), B. Nelson(2), Julie Hambleton(2), David H. Johnson(2), Waun Ki Hong(2), Hai T. Tran(2), Alan Sandler(2), Michael F. Press(2), Steven M. Anderson(2)